Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALM-1 phase 3 trial of camlipixant for refractory or unexplained chronic cough
MOH_2023-06-12_012737Phase 3Active, not recruiting
- Sponsor
- BELLUS Health Inc.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of camlipixant in refractory chronic cough (RCC) and chronic idiopathic cough (CIC) (3 arms), sponsored by BELLUS Health Inc. Primary endpoints: Change in 24-hour cough frequency at Week 12 and Safety and tolerability. Started Feb 2023; status: active, not recruiting.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on MOH_2023-06-12_012737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-12_012737.